International Extranodal NK/T-cell Lymphoma Project

International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02386813

Acronym

PINK

Enrollment

770

Registered

2015-03-12

Start date

2013-01-31

Completion date

2015-06-30

Last updated

2017-04-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal NK/T-cell Lymphoma, Nasal Type

Brief summary

This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.

Detailed description

This is a retrospective cohort study using anonymized information from patients with ENKTL. The following criteria are required: (1) Patients diagnosed with ENKTL, nasal type between January 1, 1995 and December 31, 2014; (2) Patients treated with non-anthracycline based therapy as an initial treatment. The pathology of initial diagnosis was reviewed by designated pathologists.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients diagnosed with ENKTL, nasal type * Patients diagnosed between January 1, 1995 and December 31, 2014 * Patients treated with nonanthracycline-based therapy as the initial treatment after diagnosis * Nonanthracycline-based therapy includes the following treatments: * Radiotherapy including concurrent chemoradiation * Chemotherapy not including anthracycline such as doxorubicin (e.g. SMILE, VIPD) The type of salvage treatment will not be a criterion for exclusion. Thus, patients who had received various kinds of salvage treatment including anthracycline-containing regimens can be included. Patients who had undergone autologous or allogeneic stem cell transplantation can also be included in the analysis if they satisfy the above-mentioned inclusion criteria.

Exclusion criteria

* Patients who had received anthracycline-based therapy, such as CHOP or CHOP-like regimens, as the initial treatment. * Patients who do not have pathology slides available for central review.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5 year	Time between the date of diagnosis and any kinds of death

Secondary

Measure	Time frame	Description
Progression-free survival	5 year	Time between the date of diagnosis and any kinds of death or relapse/progression

Countries

South Korea

Outcome results